Synonym
Oxiperomide; Peromide;
IUPAC/Chemical Name
3-[1-(2-Phenoxyethyl)piperidin-4-yl]-1H-benzimidazol-2-one
InChi Key
NVDBBGBUTKLRSN-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H23N3O2/c24-20-21-18-8-4-5-9-19(18)23(20)16-10-12-22(13-11-16)14-15-25-17-6-2-1-3-7-17/h1-9,16H,10-15H2,(H,21,24)
SMILES Code
O=C1N(C2CCN(CCOC3=CC=CC=C3)CC2)C4=CC=CC=C4N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
337.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Gerhardt S, Gerber R, Liebman JM. SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models. Life Sci. 1985 Dec 23;37(25):2355-63. PubMed PMID: 3908866.
2: Costall B, Kelly ME, Naylor RJ. Unilateral striatal dopamine denervation: reduced motor inhibitory effects of dopamine antagonists revealed in models of asymmetric and circling behaviour. Naunyn Schmiedebergs Arch Pharmacol. 1984 May;326(1):29-35. PubMed PMID: 6433208.
3: Bischoff S, Bittiger H, Delini-Stula A, Ortmann R. Septo-hippocampal system: target for substituted benzamides. Eur J Pharmacol. 1982 Apr 23;79(3-4):225-32. PubMed PMID: 7201401.
4: Costall B, Lim SK, Naylor RJ. Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice. Eur J Pharmacol. 1981 Jul 17;73(2-3):175-88. PubMed PMID: 6118281.
5: Neale R, Fallon S, Gerhardt S, Liebman JM. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. PubMed PMID: 6798615.
6: Liebman JM, Neale R, Noreika L, Braunwalder A. Differential reversal of various dopamine antagonists by anticholinergics in Sidman avoidance: possible relationship to adrenergic blockade. Psychopharmacology (Berl). 1981;75(3):248-53. PubMed PMID: 6119730.
7: Porsolt RD, Jalfre M. Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology (Berl). 1981;75(1):16-21. PubMed PMID: 6117919.
8: Owen RT. Intrastriatal kainic acid- a possible model for antidyskinetic/antichoreic agents? Methods Find Exp Clin Pharmacol. 1980 Apr;2(3):133-7. PubMed PMID: 7339335.
9: Casey DE, Gerlach J. Oxiperomide in tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1980 Mar;43(3):264-7. PubMed PMID: 7373324; PubMed Central PMCID: PMC490519.
10: Hyttel J. Further evidence that 3H-cis(Z)flupenthixol binds to the adenylate cyclase-associated dopamine receptor (D-1) in rat corpus striatum. Psychopharmacology (Berl). 1980 Jan;67(1):107-9. PubMed PMID: 6768074.
11: Bjørndal N, Casey D, Gerlach J. Dopamine antagonist and agonist treatment of tardive dyskinesia. Adv Biochem Psychopharmacol. 1980;24:541-5. PubMed PMID: 6105800.
12: Costall B, Naylor RJ, Nohria V. Use of the mouse circling model to demonstrate enhanced striatal actions for oxiperomide and tiapride following denervation [proceedings]. Br J Pharmacol. 1979 May;66(1):121P. PubMed PMID: 36952; PubMed Central PMCID: PMC2043833.
13: Casey DE, Gerlach J. Sulpiride and oxiperomide in tardive dyskinesia. Trans Am Neurol Assoc. 1979;104:210-1. PubMed PMID: 553412.
14: Costall B, Naylor RJ. Dopamine antagonistic effects of a series of analogues of oxiperomide and spiroxatrine measured behaviourally in the rodent. J Pharm Pharmacol. 1978 Nov;30(11):693-8. PubMed PMID: 31432.
15: Costall B, Naylor RJ, Nohria V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur J Pharmacol. 1978 Jul 1;50(1):39-50. PubMed PMID: 28233.
16: Costall B, Naylor RJ, Owen RT. Gabaminergic and serotonergic modulation of the antidyskinetic effects of tiapride and oxiperomide in the model using 2-(N,N-dipropyl)animo-5,6-dihydroxytetralin. Eur J Pharmacol. 1978 Jun 15;49(4):407-13. PubMed PMID: 352713.
17: Bédard P, Parkes JD, Marsden CD. Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. Br Med J. 1978 Apr 15;1(6118):954-6. PubMed PMID: 638546; PubMed Central PMCID: PMC1603806.
18: Costall B, Naylor RJ. Dissociation of stereotyped biting responses and oro-bucco-lingual dyskinesias. Eur J Pharmacol. 1976 Apr;36(2):423-9. PubMed PMID: 945168.
19: Costall B, Naylor RJ. Neuroleptic antagonism of dyskinetic phenomena. Eur J Pharmacol. 1975 Sep-Oct;33(2):301-12. PubMed PMID: 241654.
